Ulrike Gerdemann
Seminars
Wednesday 18th February 2026
Panel Discussion – Navigating Next-Generation GBM Immunotherapies & Delineating a Path to Clinical Success
11:00 am
- Diving into the scientific breakthroughs in GBM immunotherapies including oncolytic viruses, cell therapies and bispecific antibodies to overcome immunosuppression in the brain
- Navigating the biomarker validation process in order to identify reliable and predictive biomarkers accurately assess the effect of immunotherapies for GBM
- Advancing clinical endpoints for immunotherapies to overcome challenges involved with pseudo-progression
Wednesday 18th February 2026
Exploring Next-Generation CAR-T Treatments for Glioblastomas to Overcome the Tumor Microenvironment & Ensure Efficacy
8:30 am
- Reviewing critical lessons from past CAR-T clinical trials in GBM to highlight efficacy barriers caused by the tumor microenvironment
- Detailing next-generation CAR-T strategies designed to resist suppression through the knockdown of upstream receptors that sense TME signals to enhance CAR-T survival in the brain
- Discussing how these novel approaches can overcome GBM’s immune resistant phenotype and achieve durable and efficacious tumour clearance
Tuesday 17th February 2026
Assessing Current Clinical Biomarkers & Defining a Future Gold Standard for Surrogate Endpoints in Glioblastoma Clinical Development
11:00 am
- Join this workshop to establish a future direction towards achieving a gold standard surrogate endpoint for GBM clinical trials
- Discussing innovative, non-invasive strategies for dose selection and defining a biologically effective dose in GBM trials such as using advanced imaging biomarkers and liquid biopsies from CSF to overcome the infeasibility of serial brain biopsies
- Exploring the challenges in gaining regulatory approval and validate advanced imaging biomarkers to build a strong scientific case for their use as reliable indicators of therapeutics response
- Diving into the limitations of using ‘Progression Free Survival’ as a surrogate endpoint for overall survival in GBM due to pseudo-progression and designing trials that can use complementary endpoints to accurately differentiate between treatment-based inflammation and true disease progression
- Addressing the FDA’s hesitation to accept PFS as a standalone surrogate for accelerated approval in GBM
- Exploring alternative or composite endpoints that could meet regulatory standards
